<DOC>
	<DOCNO>NCT01747083</DOCNO>
	<brief_summary>This study design investigate food-effects FDC ( gemigliptin/metformin HCl sustain release ) 50/1000mg ( 25/500mg x 2tablets )</brief_summary>
	<brief_title>Food-Effect Bioavailability Study FDC ( Gemigliptin/Metformin HCl Sustained Release ) 50/1000mg ( 25/500mg x 2tablets )</brief_title>
	<detailed_description />
	<mesh_term>Metformin</mesh_term>
	<criteria>Age 20 45 , healthy male subject ( screen ) BMI 19.0 27.0 FPG 70125mg/dL glucose level ( screen ) Subject totally understand progress clinical trial , make decision free , signed consent form follow progress . Subject past present history disease follow . ( liver include hepatitis virus carrier , kidney , Neurology , immunology , pulmonary , endocrine , hematooncology , cardiology , mental disorder . ) Subject GI tract disease ( ulcer , acute chronic pancreatitis ) surgery . ( appendectomy , hernioplasty include ) Subject drug hypersensitivity reaction . ( Aspirin , antibiotic ) Subject already participate trial 90 day Subject whole blood donation 60 day , component blood donation 30 day transfusion 30 day currently . Smokers . ( , subject did'nt smoke 3months , participate trial )</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>